Free Trial
NASDAQ:OCUL

Ocular Therapeutix Q4 2023 Earnings Report

Ocular Therapeutix logo
$11.56 +0.13 (+1.09%)
As of 03:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ocular Therapeutix EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.28
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Ocular Therapeutix Revenue Results

Actual Revenue
$14.80 million
Expected Revenue
$15.31 million
Beat/Miss
Missed by -$510.00 thousand
YoY Revenue Growth
N/A

Ocular Therapeutix Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 11, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Ocular Therapeutix's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Ocular Therapeutix Earnings Headlines

Trump cannot stop this train
There are five truths reshaping America’s financial future — and ignoring them could be costly. From an overextended government and vanishing savings to AI-driven job displacement and a widening wealth divide, the warning signs are clear. But according to Porter Stansberry, these same forces are also driving one of the largest wealth transfers in history. His new exposé, The Final Displacement, reveals the economic blueprint behind these shifts — and the final step he believes every American must take to protect and grow their wealth before it’s too late.tc pixel
See More Ocular Therapeutix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email.

About Ocular Therapeutix

Ocular Therapeutix (NASDAQ:OCUL) is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S. Food and Drug Administration for the treatment of ocular inflammation following ophthalmic surgery. Ocular Therapeutix also markets ReSure® Sealant, a synthetic polyethylene glycol-based hydrogel approved to seal corneal incisions and reduce postoperative fluid egress. These products exemplify the company’s strategy of combining novel delivery systems with established drug compounds to enhance safety and efficacy.

In addition to its marketed therapies, Ocular Therapeutix maintains a pipeline of investigational candidates targeting conditions such as glaucoma and dry eye disease. Key programs include OTX-TKI, a tyrosine kinase inhibitor insert under development for glaucoma, and OTX-DED, an insert incorporating low-dose dexamethasone for chronic dry eye. The company leverages partnerships and licensing agreements to expand its technology platform and advance clinical programs.

Led by Chief Executive Officer Antony Mattessich, Ocular Therapeutix operates manufacturing and research facilities in the United States and collaborates with contractors and distributors to support commercialization. The company’s management team combines expertise in ophthalmology, drug delivery, and regulatory affairs to guide product approvals and market access strategies within the U.S. and select international markets.

View Ocular Therapeutix Profile

More Earnings Resources from MarketBeat